

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/304366439>

# Detection of t(8;14) C-MYC/IGH Gene Rearrangement by Long-Distance Polymerase Chain Reaction in Patients with...

Article in Hematology/ Oncology and Stem Cell Therapy · June 2016

DOI: 10.1016/j.hemonc.2016.05.006

CITATION

1

READS

65

6 authors, including:



**Sasan Andalib**

Guilan University of Medical Sciences

47 PUBLICATIONS 155 CITATIONS

[SEE PROFILE](#)



**Saeid Ghorbian**

Islamic Azad University of Ahar

34 PUBLICATIONS 60 CITATIONS

[SEE PROFILE](#)



**Ebrahim Sakhinia**

Tabriz University of Medical Sciences

83 PUBLICATIONS 387 CITATIONS

[SEE PROFILE](#)

Some of the authors of this publication are also working on these related projects:




Probiotic effect on cell signaling [View project](#)



ELSEVIER

Available at [www.sciencedirect.com](http://www.sciencedirect.com)

ScienceDirect

journal homepage: [www.elsevier.com/locate/hemonc](http://www.elsevier.com/locate/hemonc)

## ORIGINAL RESEARCH REPORT

# Detection of t(8;14) *c-myc/IgH* gene rearrangement by long-distance polymerase chain reaction in patients with diffuse large B-cell lymphoma

Arezoo Kiaei <sup>a,b</sup>, Habib Onsori <sup>c</sup>, Aylar Alijani <sup>a,b</sup>, Sasan Andalib <sup>d</sup>, Saeid Ghorbian <sup>e</sup>, Ebrahim Sakhinia <sup>f,\*</sup>

<sup>a</sup> Department of Biology, Tabriz Branch, Islamic Azad University Tabriz, Iran

<sup>b</sup> Department of Biology, College of Science, Tabriz Branch, Islamic Azad University, Tabriz, Iran

<sup>c</sup> Department of Cell and Molecular Biology, Marand Branch, Islamic Azad University, Marand, Iran

<sup>d</sup> Department of Neurosurgery, Poursina Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran

<sup>e</sup> Young Researchers and Elite Club, Ahar Branch, Islamic Azad University, Ahar, Iran

<sup>f</sup> Connective Tissue Research Center, Department of Medical Genetics, Faculty of Medicine and Tabriz Genetic Analysis Centre (TGAC), Tabriz University of Medical Sciences, Daneshgah Street, 516661557, Tabriz, Iran

Received 15 April 2016; accepted 30 May 2016

## KEYWORDS

Diffuse large B-cell lymphoma;  
Long-distance polymerase chain reaction;  
Non-Hodgkin lymphoma;  
Translocation *myc/IgH*

## Abstract

**Objective/background:** Specific chromosomal translocations are found in human leukemias and lymphomas. These translocations are closely related to particular histological and immunological phenotypes. In Burkitt's lymphoma, translocation t(8;14)(q24;q32), which involves the *c-myc* gene (8q24) and the immunoglobulin heavy-chain (*IgH*) locus (14q32), accounts for 90–95% of all chromosomal translocations. This translocation can be found in 2–5% of diffuse large B-cell lymphoma (DLBCL). Long-distance polymerase chain reaction (LD-PCR) assays, which can identify oncogene/*Ig* gene rearrangement, can detect these fusion genes. The objective of this study was to detect t(8;14) *c-myc/IgH* gene rearrangement by LD-PCR in patients with DLBCL.

**Methods:** In this study, 54 DLBCL cases were tested by LD-PCR with specific primers. LD-PCR was used for two breakpoints in both the *IgH* gene (joining region and  $\gamma$  switch region) and the *myc* gene (Exons 2 and 3).

\* Corresponding author.

E-mail address: [esakhinia@yahoo.co.uk](mailto:esakhinia@yahoo.co.uk) (E. Sakhinia).

<http://dx.doi.org/10.1016/j.hemonc.2016.05.006>

1658-3876/© 2016 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd.

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Please cite this article in press as: Kiaei A et al., Detection of t(8;14) *c-myc/IgH* gene rearrangement by long-distance polymerase chain reaction in patients with diffuse large B-cell lymphoma ..., *Hematol Oncol Stem Cell Ther* (2016), <http://dx.doi.org/10.1016/j.hemonc.2016.05.006>

**Results:** As much as 1.85% of the samples were positive for the  $\gamma$  constant region and Exon 2 of the *myc* gene.

**Conclusion:** LD-PCR can be used for the detection of t(8;14) *c-myc/IgH* gene rearrangement in patients with DLBCL.

© 2016 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Introduction

Non-Hodgkin's lymphoma (NHL) is the eighth most commonly diagnosed cancer in men and the eleventh in women [1]. The diffuse large B-cell lymphoma (DLBCL) type is the most common histological subtype of NHL. Although the treatment options for different subtypes of NHL are almost similar, DLBCL includes a heterogeneous group of NHL with different prognoses and molecular and clinical characteristics [2]. Moreover, other mature B-cell neoplasms with aggressive behavior exhibit changes in the *myc* gene [3]. Most patients with Burkitt's lymphomas and some of those with DLBCL display chromosomal translocation t(8;14)(q24;q32) accompanied by juxtaposition of the *myc* gene with enhancer elements in the immunoglobulin heavy-chain (*IgH*) gene locus. Approximately 3% of adult patients with B-lineage acute lymphoblastic leukemia show such aberration [4].

As a pleiotropic transcription factor, *myc* contributes to cellular development. It not only regulates target genes related to growth and proliferation directly, but also controls complex networks of microRNAs and apoptosis mediators. Increased expression of *myc* is seen in ~70% of all human malignancies [5]. Recombination takes place only at the DNA level and no fusion messenger RNA or fusion protein is generated. The positions of the chromosomal breakpoints in the *c-myc* gene and various *Ig* genes are widely distributed and these breaks have specific characteristics in every patient [6]. Balanced chromosomal translocations are mostly seen in mature B-cell lymphomas often involving the *Ig* genes and a variety of partner genes [7]. Because the translocated partner gene is transpositioned into the *Ig* locus, it frequently becomes transcriptionally deregulated. The frequent involvement of *Ig* loci in chromosomal translocations indicates the remodeling of *Ig* genes. This remodeling occurs during B-cell development due to V gene segment assembly, somatic hypermutation, and class-switch recombination [8]. Translocations occur head to head (5'-5') between the two loci of *c-myc* and *IgH* genes [5]. The enhancer affects the transcription of *myc* when it is juxtaposed with enhancer elements of *Ig* gene, resulting in *myc* overexpression (Fig. 1) [5,9].

Many techniques are used for detecting t(8;14) such as Southern blotting [10], fluorescent *in situ* hybridization [11], microarray [12], and long-distance polymerase chain reaction (LD-PCR) [13,14]. Many traditional techniques such as Southern blot tests have been replaced by PCR-based methods. The advantages of PCR are the low need for DNA, relatively fast process, and detection of abnormalities at a very low amount [15].

To detect the *myc/IgH* fusion in DLBCL cases, LD-PCR and touch-down PCR were performed. In the LD-PCR assay, PCR

products ranging from 1 kb to 10 kb are amplified with two forward primers specific for *myc* Exons 2 and 3 combined, in different reactions, with two reverse primers for the *IgH* locus IGHG constant ( $C\gamma$ ) and IGHJ joining (JH) regions. The touch-down PCR assay was also used for the detection of t(8;14)(q24;q32).

## Materials and methods

### Patients

In this investigation, we analyzed 54 cases of suspected lymphomas collected from the Department of Pathology, Cancer Institute of Imam Khomeini Hospital, Tehran, Iran, and Imam Reza Hospital, Tabriz, Iran, between November 2008 and August 2011. We used formalin-fixed, paraffin-embedded (FFPE) blocks. The pathological board re-evaluated all the samples and confirmed the diagnosis according to the World Health Organization classification criteria [16].

### Cell lines

The human BL cell lines, RAJI (*IGHG* breakpoint) and DG-75 (*IGHJ* breakpoint), were purchased from the cell bank of Pasteur Institute of Iran (Tehran, Iran) and maintained in Roswell Park Memorial Institute-1,640 medium with 10% fetal calf serum. The genomic DNA, which was used as positive control in the PCRs, was then isolated from cultured cell lines.




### Template DNA extraction

From each FFPE tissue, 4- or 5- $\mu$ m sections were obtained, and transferred into sterile containers and stored at room temperature until their use in DNA extraction. DNA was extracted from the FFPE specimens using the FFPE DNA extraction kit as described by the manufacturer (Quick Extract FFPE DNA Extraction; Epicentre, Madison, WI, USA).

To evaluate the quality and quantity of the extracted DNA [15], it was amplified by PCR and UV spectrophotometry at 260/280 nm using the NanoDrop ND-1,000 spectrophotometer (NanoDrop Technology, Wilmington, DE, USA). The average concentration of the DNA samples was 155 ng/ $\mu$ L (range 120–560 ng/ $\mu$ L) and its OD<sub>260/280</sub> ratio was 1.87.

### Primers

To detect the rearrangement involving the *c-myc* gene on Chromosome 8q24 and the *IgH* locus on Chromosome

**A Chromosome 8q24: c-myc gene****B Chromosome 14q32: IGH locus****C der 14 t(8;14) (q24;q32)**

**Fig. 1** Positions of *c-myc/IgH* breakpoints in DLBCL and detection by LD-PCR. (A) Map of the human *c-myc* gene on Chromosome 8; (B) the *IgH* locus on Chromosome 14. (C) Prototypical *c-myc/IgH* fusion gene in DLBCL showing position breakpoints, and forward and reverse primers that are used for LD-PCR. LD-PCR performed for the JH and  $\gamma$  constant regions. *Note.* bp = base pair; DLBCL = diffuse large B-cell lymphoma; LD-PCR = long-distance polymerase chain reaction.

14q32, two primers for the *c-myc* gene and two primers for the *IgH* locus were combined. One primer for the IGHG constant region ( $C\gamma$ ) and another one for IGHJ of the joining region (JH) were used (Table 1).

**Long-distance polymerase chain reaction**

LD-PCR refers to the amplification of DNA lengths that cannot typically be amplified using routine PCR methods or reagents. For simple DNA templates, polymerases optimized

for long-range PCR can amplify  $\sim 30$  kb. Each reaction mixture (25  $\mu$ L) contained 300 ng of DNA genome, 10 pM downstream and upstream primers, 500  $\mu$ M of each deoxyribose nucleoside triphosphate, 10 $\times$  buffer with 4 mM  $MgCl_2$ , and 2 units of KBC Extend long polymerase enzyme mix as indicated in the KBC Extend long PCR kit (Kawsar Biotech Company, Tehran, Iran).

LD-PCR was performed in two steps. In the first step, the reaction condition was as follows: an initial denaturation at 94  $^{\circ}C$  for 4 min followed by 15 cycles of denaturation at 94  $^{\circ}C$

**Table 1** Primers used for LD-PCR.

FORWARD	REVERSE
MYC/M6: 5'ACAGTCCTGGATGATGATGTTTTTGGATGAAGGTCT3'	JH: 5'CTTACCTGAGGAGACGGTGACCGTGGTCCC3'
MYC/M9: 5'GAGATCCTCTGGGGTTTGCAGATAACCCATGG3	C: 5'GGTACCACGCTGCTGAGGGAGTAGAGT3'

C for 20 s, annealing at 60 °C for 50 s, extension at 68 °C for 4 min, and a final extension for 10 min at 68 °C. In the second step, the reaction condition was as follows: an initial denaturation at 94 °C for 4 min followed by 12 cycles of denaturation at 94 °C for 10 s, annealing at 65 °C for 30 s, extension at 68 °C for 4 min with gradual increments of the extension time (20 s/cycle), and a final extension for 10 min at 68 °C.

PCR products were analyzed by agarose gel electrophoresis (0.8% agarose in Tris base–acetic acid–EDTA buffer stained with ethidium bromide) and visualized under a UV transilluminator.

## Results

Based on the structure of the genes involved in the t(8;14) (q24;q32) translocation, we selected a limited number of primers bracketing the breakpoints and specific for Exon 2 of the *myc* gene and for the joining and constant regions of the *IgH* gene. In the PCRs, an antisense primer in *myc* Exon 2 (*myc/M6*) was combined with an antisense primer in the CH1 exons of IGHG or in the sixth joining segment of IGHJ. Each investigation included two positive and negative controls. PCR conditions were optimized to fit a set of primers for reproducing the translocation. Primers and reaction conditions were first tested in two Burkitt's cell


lines with cytogenetically proven t(8;14), using the same *myc*-specific primer in different reactions in combination with each primer recognizing a selected *IgH* region.

We obtained a PCR product with sizes of 1.5 kb and 7.6 kb in DG75 and RAJI cell lines, respectively. DG75 cells were positive for the JH breakpoint with the primer specific for the JH region and RAJI cells were positive for the C $\gamma$  breakpoint when using the C $\gamma$  primer. The LD-PCR was performed for 54 cases to detect t(8;14). One patient (a 55-year-old man) was positive for the *myc/M6* and C $\gamma$  primer pair (Fig. 2). The 53 LD-PCR-negative patients were tested with the *myc-9* primer (positioned in Intron 3) in combination with the C $\gamma$  primer to establish whether breakpoints could be located downstream of Exon 2 in the *c-myc* gene. The results showed all of them to be negative for these breakpoints. Existence of a PCR product was investigated in the cases using LD-PCR for the *myc-6* and JH primer pair. However, none of them showed any PCR product. Patients negative for the joining region (JH) breakpoint were re-examined with touch-down PCR. No PCR product was produced with this method either.

## Discussion

DLBCL is a heterogeneous disease comprising 30% of adult NHLs. It has different subtypes and clinical outcomes [17]. Considering the curable nature of the disease by suitable treatment, it is crucial to identify infiltration of lymphomatous for determination of the state of the disease accurately as well as evaluation of the therapy [18]. Most DLBCLs are accurately diagnosed using immunohistochemistry or flow cytometric immunophenotyping. However, diagnosis becomes complicated in ~5–10% of the patients [19,20]. In these patients, molecular gene rearrangement studies have been found to be useful as a complementary diagnostic tool [21]. The t(8;14) translocation is common in Burkitt's lymphoma and a subset of DLBCL [4]. The *myc* oncogene on Chromosome 8 and the *IgH* locus on Chromosome 14 are involved in this translocation. The *c-myc* gene consists of three exons, among which Exons 2 and 3 include the coding sequence for the *c-myc* protein. Because of sequences that block transcriptional elongation, Exon 1 encodes an untranslated sequence acting as a negative regulatory sequence. The negative regulatory Exon 1 and Intron 1 sequences are removed in some lymphomas because the t(8;14) breakpoints tend to be in the first intron [22].

The *Ig*-enhancer elements that contribute to *c-myc* dysregulation specifically stimulate transcription in B cells normally. The *IgH* E $\mu$  or E $\alpha$  enhancer in the *c-myc* coding sequences can potentially induce B-cell tumors, suggesting that in tumors with translocation t(8;14), *IgH* elements *per se* might increase oncogenic levels of *c-myc* expression



**Fig. 2** Ethidium bromide-stained gel electrophoresis of long-distance polymerase chain reaction. L, C, and N, respectively, are ladder, positive control (RAJI cell line), and negative control. S29–S16 are samples showing the *myc/IgH* translocation in the  $\gamma$  breakpoint. The size of the product is 7,600 bp. Others were negative for this translocation. *Note.* bp = base pair; *IgH* = immunoglobulin heavy-chain locus.

[23]. The LD-PCR can identify t(8;14) at the genomic level, and is therefore useful for this translocation considering that it does not produce a fusion gene [24]. Moreover, it can be applied to translocations in which the DNA sequences of the regions immediately adjacent to the breakpoint have not yet been identified. The other advantage is that amplified fragments have sequences unique to individual patients. Thus, this PCR technique could be applied to analyze translocations in leukemia. PCR using DNA is considerably easier than RT-PCR, which requires RNA isolation and complementary DNA synthesis.

DLBCL of B-cell phenotype comprises 30–40% of adult NHL [25] and is a good candidate for such an aggressive treatment. Therefore, sensitive genetic markers of this particular lymphoma subtype are required for assessing minimal residual disease [17]. Translocations involving *myc* are also found in other hematological malignancies in addition to Burkitt's lymphoma, most importantly in the subsets of DLBCL. In this tumor, a chromosomal translocation at the *myc* locus shows a more aggressive tumor phenotype and a lower survival rate [26]. Two to five percent of DLBCLs are affected by the t(8;14) translocation in several breakpoints in the *myc* (Exons 2 and 3) and *IgH* genes (Jh, C $\mu$ , C $\gamma$ , C $\delta$ , C $\alpha$ , and C $\epsilon$ ). We performed LD-PCR only for the JH region and one constant region ( $\gamma$ ) with Exon 2 of the *myc* gene in 54 samples. In lymphoma patients with JH break, the positions of the *IgH*  $\mu$  enhancer affects transcription of the *myc* gene. The breaks in the *IgH* gene occur during attempted V(D)J recombination, leading to the juxtaposition of the IgH enhancer with *c-myc*. However, with respect to the  $\gamma$  switch region, the breakpoints in the *IgH* gene occur during attempted Ig switching, leading to the juxtaposition of 3' *IgH*-enhancer elements (such as E $\alpha$ ) with sequences of *c-myc*. These enhancers affect *myc*'s promoter and expression of *myc*. Only one patient was positive (1.85%) for the  $\gamma$  breakpoint. However, in negative samples, it is suggested that translocation happened in other breakpoints. DLBCL can affect any age group, but mostly occurs in elderly patients (normally in people in the mid-60s). Therefore, LD-PCR can be used for the detection of t(8;14) *c-myc/IgH* gene rearrangement in patients with DLBCL.

## Conflicts of interest

All contributing authors declare no conflicts of interest.

## Acknowledgments

We are grateful to Dr. S. Dastmalchi, Dr. M. Hamzemiveh-rod, Dr. A. Y. Khosroushahi, Dr. O. Zarei, and A. Barzegar from the Biotechnology Research Center, Tabriz University of Medical Sciences, who helped us in this study.

## References

- [1] Boffetta P. Epidemiology of adult non-Hodgkin lymphoma. *Ann Oncol* 2011;22(Suppl. 4):iv27–31.
- [2] Zhou K, Xu D, Cao Y, Wang J, Yang Y, Huang M. C-MYC aberrations as prognostic factors in diffuse large B-cell lymphoma: a meta-analysis of epidemiological studies. *PLoS One* 2014;9:e95020.
- [3] Ott G, Rosenwald A, Campo E. Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification. *Blood* 2013;122:3884–91.
- [4] Burmeister T, Molkentin M, Schwartz S, Gökbuget N, Hoelzer D, Thiel E, et al. Erroneous class switching and false VDJ recombination: molecular dissection of t(8;14)/MYC-IGH translocations in Burkitt-type lymphoblastic leukemia/B-cell lymphoma. *Mol Oncol* 2013;7:850–8.
- [5] Klapproth K, Wirth T. Advances in the understanding of MYC-induced lymphomagenesis. *Br J Haematol* 2010;149:484–97.
- [6] Busch K, Borkhardt A, Wössmann W, Reiter A, Harbott J. Combined polymerase chain reaction methods to detect *c-myc/IgH* rearrangement in childhood Burkitt's lymphoma for minimal residual disease analysis. *Haematologica* 2004;89:818–25.
- [7] Gaidano G, Dalla-Favera R. Molecular biology of lymphomas. In: Devita Jr VT, Hellman S, Rosenberg S, editors. *Cancer: principles and practice of oncology*. Philadelphia, PA: JB Lippincott Company; 1997. p. 2131–45.
- [8] Küppers R, Dalla-Favera R. Mechanisms of chromosomal translocations in B cell lymphomas. *Oncogene* 2001;20:5580–94.
- [9] Hecht JL, Aster JC. Molecular biology of Burkitt's lymphoma. *J Clin Oncol* 2000;18:3707–21.
- [10] Pelicci PG, Knowles 2nd DM, Magrath I, Dalla-Favera R. Chromosomal breakpoints and structural alterations of the *c-myc* locus differ in endemic and sporadic forms of Burkitt lymphoma. *Proc Natl Acad Sci USA* 1986;83:2984–8.
- [11] Siebert R, Matthiesen P, Harder S, Zhang Y, Borowski A, Zühlke-Jenisch R, et al. Application of interphase fluorescence *in situ* hybridization for the detection of the Burkitt translocation t(8;14)(q24;q32) in B-cell lymphomas. *Blood* 1998;91:984–90.
- [12] Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. *Nature* 2000;403:503–11.
- [13] Mussolin L, Pillon M, d'Amore ES, Conter V, Piglione M, Lo Nigro L, et al. Minimal disseminated disease in high-risk Burkitt's lymphoma identifies patients with different prognosis. *J Clin Oncol* 2011;29:1779–84.
- [14] Burmeister T, Schwartz S, Horst HA, Rieder H, Gökbuget N, Hoelzer D, et al. Molecular heterogeneity of sporadic adult Burkitt-type leukemia/lymphoma as revealed by PCR and cytogenetics: correlation with morphology, immunology and clinical features. *Leukemia* 2005;19:1391–8.
- [15] Arber DA. Molecular diagnostic approach to non-Hodgkin's lymphoma. *J Mol Diagn* 2000;2:178–90.
- [16] Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. *Blood* 2011;117:5019–32.
- [17] Stasik CJ, Nitta H, Zhang W, Mosher CH, Cook JR, Tubbs RR, et al. Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma. *Haematologica* 2010;95:597–603.
- [18] Akasaka T, Muramatsu M, Ohno H, Miura I, Tatsumi E, Fukuhara S, et al. Application of long-distance polymerase chain reaction to detection of junctional sequences created by chromosomal translocation in mature B-cell neoplasms. *Blood* 1996;88:985–94.
- [19] Sandberg Y, van Gastel-Mol EJ, Verhaaf B, Lam KH, van Dongen JJ, Langerak AW. BIOMED-2 multiplex immunoglobulin/T-cell receptor polymerase chain reaction protocols can reliably replace Southern blot analysis in routine clonality diagnostics. *J Mol Diagn* 2005;7:495–503.

- [20] van Dongen JJ, Langerak AW, Brüggemann M, Evans PA, Hummel M, Lavender FL, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 concerted action BMH4-CT98-3936. *Leukemia* 2003;17:2257–317.
- [21] van Dongen JJ, Wolvers-Tettero IL. Analysis of immunoglobulin and T cell receptor genes. Part I: Basic and technical aspects. *Clin Chim Acta* 1991;198:1–91.
- [22] Bentley DL, Groudine M. A block to elongation is largely responsible for decreased transcription of c-myc in differentiated HL60 cells. *Nature* 1986;321:702–6.
- [23] Palomo C, Zou X, Nicholson IC, Bützler C, Brüggemann M. B-cell tumorigenesis in mice carrying a yeast artificial chromosome-based immunoglobulin heavy/c-myc translocus is independent of the heavy chain intron enhancer (Emu). *Cancer Res* 1999;59:5625–8.
- [24] Mussolin L, Basso K, Pillon M, D'Amore ES, Lombardi A, Luzzatto L, et al. Prospective analysis of minimal bone marrow infiltration in pediatric Burkitt's lymphomas by long-distance polymerase chain reaction for t(8;14)(q24;q32). *Leukemia* 2003;17:585–9.
- [25] Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. *Blood* 1994;84:1361–92.
- [26] Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth TF, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. *N Engl J Med* 2006;354:2419–30.